Document is current
Any future updates will be listed below
-
Authors
Shahi, Shailesh K.
Ghimire, Sudeep
Jensen, Samantha N.
Lehman, Peter C.
Rux, Allison G.
Sinha, Souradip
Borcherding, Nicholas
Tanas, Munir R.
Gibson-Corley, Katherine N.
Ganesan, Sukirth M.
Karandikar, Nitin J.
Mangalam, Ashutosh K. https://orcid.org/0000-0002-9926-2531
-
Funding
Funding for this research was provided by:
National Institutes of Health/NIAID (R01AI137075)
Veteran Affairs Merit Award (1I01CX002212)
- License Information
-
More Information
Article History
Received: 16 January 2025
Accepted: 26 February 2026
First Online: 29 June 2026
Declarations
:
: All experiments were approved by the Institutional Animal Care and Use Committee at the University of Iowa.
: Not applicable.
: AKM is the inventor of a technology claiming the use of Prevotella histicola for the treatment of autoimmune diseases. The patent for the technology is owned by the Mayo Clinic, which has given an exclusive license to Evelo Biosciences. AKM received royalties from Mayo Clinic (paid by Evelo Biosciences). However, no funds or products from the patent were used in the present study. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
